WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in … WebbPHIO / Phio Pharmaceuticals Corp off-exchange short sale volume is shown in the following chart. Short Sale volume shows the number of trades marked as short sales in …
PHIO - Phio Pharmaceuticals Corp. Stock Price and Quote
WebbResumen PHIO Gráfico técnico Phio Pharmaceuticals Corp 5,527 + 0,259 ( + 4,92 %) S 1 semana 1 año Máx. Último cierre 5,268 Rango día 5,321 - 6 Ingresos - Apertura 5,321 52 semanas 3,9 - 29,04... Webb22 feb. 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. Corporate Presentation The following is an investor update, effective January 2024, presented by Robert Bitterman. Mr. philip and kelvin laverne coffee table value
PHIO / Phio Pharmaceuticals Corp - Net Long/Short Value
WebbPHIO Short Sale Transactions - Phio Pharmaceuticals Corp EXTENDED. Day's Range - 52 Week Range - WebbPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update. Additional Formats PDF Version. February 22, 2024 Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer. Additional Formats PDF Version. February 13, 2024 ... WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. philip and james